Pharmaceuticals
Pharma - Formulators
from 3,436 today
Ajanta Pharma reported revenue of Rs. 16,260 Mn, up 24.8% YoY, exceeding estimates, driven by strong domestic, Africa branded generics, and US generics performance. We maintain our BUY rating with a Target Price of Rs. 4,007 based on 35x FY28E EPS.
Ajanta Pharma's Q1FY27 results were ahead of expectations, driven by solid traction in India and Africa. We downgrade the stock to HOLD on expensive valuations, while raising our target price to INR 3,260.
Ajanta Pharma delivered a better-than-expected 1QFY26, driven by robust revenue growth in the US, India, and Africa. We expect a 15%/16%/16% CAGR in revenue/EBITDA/PAT over FY26-28 and reiterate our BUY rating with a target price of INR4,000.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
